PREMARKET WATCH: Amylin Pharmaceuticals (AMLN)

Posted in General 
July 22nd, 2009

Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) shares fell nearly 5 percent to $12.69 on more than 100,000 shares traded after hours, and are ones to watch for a potential downside volume spike this morning. The company posted Q2 EPS last night of 36 cents a share, missing analyst expectations by a penny a share. Revenue fell 5.7 percent from a year earlier to $209.4 million, slightly beating consensus of $205.1 million. Sales of its diabetes drug Byetta were $175.1 million, above expectations of $164 million. — Mike Tarsala

Comments are closed